What is the best glomerular filtration marker to identify people with chronic kidney disease most likely to have poor outcomes?

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Lamb, E J ^a   Stevens, P E ^a   Deeks, J J ^b  

^a EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYSTATIN C; BIOLOGICAL MARKER;

ADVERSE OUTCOME; ALBUMINURIA; CHRONIC KIDNEY DISEASE; CLINICAL STUDY; CREATININE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; DISEASE COURSE; MASS SCREENING; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; MASS SCREENING; PREDICTIVE VALUE OF TESTS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84921368963     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g7667     Document Type: Review

References (28)

1. Kidney Disease Improving Global Outcomes. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013;3(suppl.):1-150.
2. Levin A, Stevens PE. Early detection of CKD: the benefits, limitations and effects on prognosis. Nat Rev Nephrol 2011;7:446-57.
3. Foote C, Clayton PA, Johnson DW, Jardine M, Snelling P, Cass A. Impact of estimated GFR reporting on late referral rates and practice patterns for end-stage kidney disease patients: a multilevel logistic regression analysis using the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Am J Kidney Dis 2014;64:359-66.
4. Moynihan R, Doust J, Henry D. Preventing overdiagnosis: how to stop harming the healthy. BMJ 2012;344:e3502.
5. Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 2012;156:785-95.
6. Johnson DW, Jones GR, Mathew TH, Ludlow MJ, Doogue MP, Jose MD, et al. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. Med J Aust 2012;197:224-5.
7. National Institute for Health and Care Excellence. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. NICE, 2014 (available at www.nice.org.uk/guidance/cg182).
8. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. A new equation to estimate glomerular filtration rate from standardized creatinine and cystatin C. N Engl J Med 2012;367:20-9.
9. Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012;307:1941-51.
10. Matsushita K, Tonelli M, Lloyd A, Levey AS, Coresh J, Hemmelgarn BR. Clinical risk implications of the CKD Epidemiology Collaboration (CKD-EPI) equation compared with the Modification of Diet in Renal Disease (MDRD) Study equation for estimated GFR. Am J Kidney Dis 2012;60:241-9.
11. Waheed S, Matsushita K, Astor BC, Hoogeveen RC, Ballantyne C, Coresh J. Combined association of creatinine, albuminuria, and cystatin C with all-cause mortality and cardiovascular and kidney outcomes. Clin J Am Soc Nephrol 2013;8:434-42.
12. Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 2011;22:147-55.
13. Shastri S, Katz R, Shlipak MG, Kestenbaum B, Peralta CA, Kramer H, et al. Cystatin C and albuminuria as risk factors for development of CKD stage 3: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2011;57:832-40.
14. Shlipak MG, Matsushita K, Arnlov J, Inker LA, Katz R, Polkinghorne KR, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013;369:932-43.
15. Waheed S, Matsushita K, Sang Y, Hoogeveen R, Ballantyne C, Coresh J, et al. Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2012;60:207-16.
16. Foster MC, Inker LA, Levey AS, Selvin E, Eckfeldt J, Juraschek SP, et al. Novel filtration markers as predictors of all-cause and cardiovascular mortality in US adults. Am J Kidney Dis 2013;62:42-51.
17. Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011;305:1545-52.
18. Tangri N, Inker LA, Tighiouart H, Sorensen E, Menon V, Beck G, et al. Filtration markers may have prognostic value independent of glomerular filtration rate. J Am Soc Nephrol 2012;23:351-9.
19. Rule AD, Glassock RJ. GFR estimating equations: getting closer to the truth? Clin J Am Soc Nephrol 2013;8:1414-20.
20. Padala S, Tighiouart H, Inker LA, Contreras G, Beck GJ, Lewis J, et al. Accuracy of a GFR estimating equation over time in people with a wide range of kidney function. Am J Kidney Dis 2012;60:217-24.
21. Xie D, Joffe MM, Brunelli SM, Beck G, Chertow GM, Fink JC, et al. A comparison of change in measured and estimated glomerular filtration rate in patients with nondiabetic kidney disease. Clin J Am Soc Nephrol 2008;3:1332-8.
22. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 2014;63:713-35.
23. Lamb EJ, Brettell EA, Cockwell P, Dalton N, Deeks JJ, Harris K, et al. The eGFR-C study: accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease - prospective longitudinal study in a multiethnic population. BMC Nephrol 2014;15:13.
24. Hemmelgarn BR, Zhang J, Manns BJ, Tonelli M, Larsen E, Ghali WA, et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int 2006;69:2155-61.
25. Kwong YT, Stevens LA, Selvin E, Zhang YL, Greene T, Van Lente F, et al. Imprecision of urinary iothalamate clearance as a gold-standard measure of GFR decreases the diagnostic accuracy of kidney function estimating equations. Am J Kidney Dis 2010;56:39-49.
26. Li L, Astor BC, Lewis J, Hu B, Appel LJ, Lipkowitz MS, et al. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis 2012;59:504-12.
27. O'Hare AM, Batten A, Burrows NR, Pavkov ME, Taylor L, Gupta I, et al. Trajectories of kidney function decline in the 2 years before initiation of long-term dialysis. Am J Kidney Dis 2012;59:513-22.
28. Carville S, Wonderling D, Stevens P. Early identification and management of chronic kidney disease in adults: summary of updated NICE guidance. BMJ 2014;349:g4507.